#USA #Chicago #CDMO #ESTEVE #Regis Technologies

ESTEVE Expands Presence and Capabilities in the US

In a significant strategic move, ESTEVE has taken a step towards enhancing its footprint in the United States by acquiring Regis Technologies, a Chicago-based Contract Development and Manufacturing Organization (CDMO). This acquisition enables ESTEVE to broaden its service offerings in the development and production of active pharmaceutical ingredients (APIs) based on small molecules, serving clients from the preclinical phase right through to commercial manufacturing.

A New Chapter for ESTEVE's CDMO Services

With this acquisition, ESTEVE aims to solidify its presence in the lucrative US pharmaceutical market, an essential step in its commitment to improve lives through better healthcare solutions. For over 65 years, Regis Technologies has been a trusted partner for pharmaceutical and biotechnological firms, specializing in a variety of services that include process research and development, stability analysis, cGMP-compliant API manufacturing, and support for chemistry and manufacturing control (CMC) processes.

Joan Petit, ESTEVE’s Chief Industrial Operations Officer and Managing Director of Esteve CDMO (operating under the Esteve Química brand), expressed pride in the enhancement of their team and CDMO solutions. The acquisition not only increases ESTEVE's manufacturing and development capabilities but also brings on board approximately 70 highly skilled individuals dedicated to advancing the CDMO sector.

Broader Implications for ESTEVE and the Pharmaceutical Industry

This acquisition aligns with ESTEVE's overarching strategy to expand its range of integrated services. According to Staffan Schüberg, ESTEVE's CEO, “The United States represents a strategic market for ESTEVE. This acquisition moves us closer to our goal of improving the lives of individuals by increasing our CDMO capabilities in this region and expanding our integrated service offerings.” This illustrates ESTEVE's long-term vision to create value not only for the company but also for its partners and clients.

Scott Aladeen, President and CEO of Regis Technologies, highlighted the cultural fit between the two companies, saying, “We are excited to join a company that shares our values and has over 90 years of commitment to people and long-term value creation for clients.”

ESTEVE: A Vision to Improve Lives

ESTEVE, founded in 1929 and headquartered in Barcelona, has built a robust international presence, with subsidiaries across several countries including Portugal, Italy, Germany, France, the UK, and now the USA. The company focuses on providing highly specialized treatments targeting significant unmet medical needs across various therapeutic areas.

Moreover, ESTEVE is not merely a pharmaceutical manufacturer; it offers comprehensive contract manufacturing and development services (CDMO), specializing in the production of APIs through state-of-the-art facilities located in Spain, Mexico, and China, alongside its new US-based operations.

The company's strong commitment to its core values—emphasizing the importance of people, transparency, and accountability—underscores all its endeavors. It is clear that ESTEVE is poised to leverage this acquisition not just for growth, but also to enhance the quality of healthcare solutions offered globally.

In sum, ESTEVE's acquisition of Regis Technologies marks a pivotal moment in its strategic growth plans, demonstrating an unwavering commitment to innovation and customer service in the pharmaceutical sector. As ESTEVE expands its capabilities, it is set to play a vital role in shaping the future of pharmaceutical manufacturing and development.